SOL-GEL TECHN. IS-10 (4SG) - Total Assets
Based on the latest financial reports, SOL-GEL TECHN. IS-10 (4SG) holds total assets worth €53.76 Million EUR (≈ $62.85 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SOL-GEL TECHN. IS-10 - Total Assets Trend (2021–2025)
This chart illustrates how SOL-GEL TECHN. IS-10's total assets have evolved over time, based on quarterly financial data. Also see 4SG market cap overview for the company's overall valuation and market capitalisation.
SOL-GEL TECHN. IS-10 - Asset Composition Analysis
Current Asset Composition (December 2025)
SOL-GEL TECHN. IS-10's total assets of €53.76 Million consist of 90.2% current assets and 9.9% non-current assets. Review 4SG current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 36.9% |
| Accounts Receivable | €1.97 Million | 6.6% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how SOL-GEL TECHN. IS-10's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest SOL-GEL TECHN. IS-10 stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SOL-GEL TECHN. IS-10's current assets represent 90.2% of total assets in 2025, an increase from 82.5% in 2021.
- Cash Position: Cash and equivalents constituted 36.9% of total assets in 2025, up from 29.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 6.6% of total assets.
SOL-GEL TECHN. IS-10 Competitors by Total Assets
Key competitors of SOL-GEL TECHN. IS-10 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
SOL-GEL TECHN. IS-10 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.37 | 7.32 | 5.81 |
| Quick Ratio | 10.37 | 7.32 | 5.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €46.15 Million | €31.31 Million | €31.42 Million |
SOL-GEL TECHN. IS-10 - Advanced Valuation Insights
This section examines the relationship between SOL-GEL TECHN. IS-10's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.59 |
| Latest Market Cap to Assets Ratio | 6.29 |
| Asset Growth Rate (YoY) | -16.5% |
| Total Assets | €29.92 Million |
| Market Capitalization | $188.25 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values SOL-GEL TECHN. IS-10's assets at a significant premium (6.29x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: SOL-GEL TECHN. IS-10's assets decreased by 16.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SOL-GEL TECHN. IS-10 (2021–2025)
The table below shows the annual total assets of SOL-GEL TECHN. IS-10 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €29.92 Million ≈ $34.98 Million |
-16.54% |
| 2024-12-31 | €35.85 Million ≈ $41.91 Million |
-20.85% |
| 2023-12-31 | €45.29 Million ≈ $52.95 Million |
-2.88% |
| 2022-12-31 | €46.63 Million ≈ $54.51 Million |
-32.61% |
| 2021-12-31 | €69.19 Million ≈ $80.89 Million |
-- |
About SOL-GEL TECHN. IS-10
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more